A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
This study tests a new experimental medicine called 3HP-2827 in adults with advanced solid tumors that have specific changes in a gene called FGFR2. Researchers want to find the safest and most effective dose of this new drug to help patients who have limited treatment options.
You may be able to join if you are 18 or older, have a confirmed advanced solid tumor with FGFR2 gene changes, and are generally well enough to do daily activities. However, people with certain heart, eye, or active brain conditions, or recent other cancers, will not be able to participate.
During the study, you will receive the investigational medicine 3HP-2827 while doctors closely monitor your health and how your body reacts to the treatment. The study starts by testing different doses to find the right amount, followed by a larger group phase to see how well it works.
The study takes place at medical centers in Phoenix, Arizona, and Houston, Texas, in the United States. It is not yet recruiting patients, but will open for enrollment soon.
- 1Evaluating a new investigational drug named 3HP-2827 for advanced solid tumors
- 2Focuses on tumors with specific genetic changes known as FGFR2 alterations
- 3Currently not yet recruiting, with study locations in Arizona and Texas
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.